The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The role of interleukin 1 in growth and metastasis of human cancer xenografts.
Abstract
BACKGROUND: Interleukin 1 (IL-1) is a pluripotent cytokine that promotes angiogenesis, tumor growth, and metastasis in experimental models; its presence in some human cancers is associated with aggressive tumor biology. The purpose of these studies was to characterize the role of IL-1 in human cancers and determine if inhibition of IL-1 via its receptor antagonist, IL-1Ra, alters tumor growth and metastatic potential. METHODS: IL-1 mRNA or protein levels were determined in clinical tumor samples, cancer cell lines, and xenografts using quantitative reverse transcription-PCR or ELISA. Biological activity of tumor-derived IL-1 protein was shown via induction of permeability across endothelial cell monolayers. The effects of recombinant IL-1Ra on tumor lines in culture (cell proliferation and IL-8 secretion) and in xenograft models (tumor growth, metastatic potential, and intratumoral levels of IL-8 and VEGF) were characterized. The effects of IL-1Ra-mediated regression of xenograft growth on angiogenic proteins (IL-8 and VEGF) were evaluated in an IL-1-producing melanoma (SMEL) xenograft model. RESULTS: IL-1 mRNA was highly expressed in more than half of all tested metastatic human tumor specimens including non-small-cell lung carcinoma, colorectal adenocarcinoma, and melanoma tumor samples. Constitutive IL-1 mRNA expression was identified in several cancer cell lines; tumor supernatant from these cell lines produced a significant increase in endothelial cell monolayer permeability, a hallmark event in early angiogenesis, in an IL-1-dependent manner. Moreover, systemic recombinant IL-1Ra resulted in significant inhibition of xenograft growth and neovessel density of IL-1-producing, but not non-IL-1-producing, tumor cell lines. Subsequent analysis of SMEL, a melanoma cell line with constitutive IL-1 production, showed that neither exogenous IL-1 nor IL-1Ra altered tumor cell proliferation rates in vitro. Gene expression analyses of IL-1Ra-treated SMEL xenografts showed a >3-fold down-regulation of 100 genes compared with control including a marked down-regulation of IL-8 and VEGF. CONCLUSIONS: These data show that the IL-1 gene is frequently expressed in metastases from patients with several types of human cancers. IL-1Ra inhibits xenograft growth in IL-1-producing tumors but has no direct antiproliferative effects in vitro; decreased tumor levels of IL-8 and VEGF may be an early surrogate of IL-1Ra-mediated antitumor activity. IL-1Ra may have a role alone or with other agents in the treatment of human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heid, C. A., Stevens, J., Livak, K. J., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,174
Opal, S. M., Fisher, C. J., Dhainaut, J.-F. A., Vincent, J.-L., Brase, R., Lowry, S. F., Sadoff, J. C., Slotman, G. J., Levy, H., Balk, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 865
Interleukin-1, Interleukin-1 Receptors and Interleukin-1 Receptor Antagonist
Dinarello, C. A. (1998) · International Reviews of Immunology · doi:10.3109/08830189809043005 · Cited by 761
High-fidelity mRNA amplification for gene profiling
Wang, E., Miller, L. D., Ohnmacht, G. A., Liu, E. T., & Marincola, F. M. (2000) · Nature Biotechnology · doi:10.1038/74546 · Cited by 675
Interleukin-1 Receptor Antagonist
Arend, W. P. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60535-0 · Cited by 671
Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.
Arend, W. P. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115453 · Cited by 595
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
Chen, Z., Malhotra, P. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., Smith, C. W., Enamorado, I. I., Yeh, N. T., Kroog, G. S., Rudy, S., et al. (1999) · PubMed · Cited by 486
Jiang, Y., Genant, H. K., Watt, I., Cobby, M., Bresnihan, B., Aitchison, R., & McCabe, D. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200005)43:5<1001::aid-anr7>3.0.co;2-p · Cited by 399
The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-1
Dinarello, C. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431011 · Cited by 373
Cytokine traps: multi-component, high-affinity blockers of cytokine action
Economides, A. N., Carpenter, L. R., Rudge, J. S., Wong, V., Koehler-Stec, E. M., Hartnett, C., Pyles, E. A., Xu, X., Daly, T. J., Young, M. R., et al. (2003) · Nature Medicine · doi:10.1038/nm811 · Cited by 359
Cited by
Inflammasomes in carcinogenesis and anticancer immune responses
Zitvogel, L., Kepp, O., Galluzzi, L., & Kroemer, G. (2012) · Nature Immunology · doi:10.1038/ni.2224 · Cited by 593
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions
Apte, R. N., Dotan, S., Elkabets, M., White, M. R., Reich, E., Carmi, Y., Song, X., Dvozkin, T., Krelin, Y., & Voronov, E. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9004-4 · Cited by 593
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Artinyan, A., Orcutt, S. T., Anaya, D. A., Richardson, P., Chen, G. J., & Berger, D. H. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000854 · Cited by 345
Metadata
- Authors
- Elaraj, D. M., Weinreich, D. M., Varghese, S., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., Turner, E. M., & Alexander, H. R.
- Venue
- Clinical Cancer Research
- Published
- 2006-02-15
- Volume
- 12
- Issue
- 4
- Pages
- 1088-1096
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2145158999
- Cited by
- 288
- References
- 35
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of interleukin 1 in growth and metastasis of human cancer xenografts. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-1603
- The paper
- Elaraj, D. M., Weinreich, D. M., Varghese, S., Puhlmann, M., Hewitt, S. M., Carroll, N. M., Feldman, E. D., Turner, E. M., & Alexander, H. R. (2006). The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-1603
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.